Methodology Depending on the pathological knowledge, the following assisted reproductive technologies (ART) were used: conservative surgery of the reproductive organs in the early stages of disease, ovarian stimulation followed by cryopreservation techniques (of embryos, oocytes, ovarian cortex and semen), interoperation collecting of the ovarian cortex for the oocyte in-vitro maturation (OTO-IVM). The exclusion criteria were a high extension of the oncological process, poor oncological prognosis, menopausal ovarian reserve.

Results Since March 2021 in N.N. Petrov NMRC of oncology in were consulted 370 primary patients: 314 women (83%) and 56 men (15%). The oncological disease’s distribution was as follows: 31% (115 patients) reproductive system malignant tumors, 26% (96 patients) breast tumors, 15% (55 patients) with hemoblastoses, 10.2% (38 patients) bone and soft tissue tumors, 8.7% (32 patients) with germ cell tumors, 9.1% (34 patients) with tumors of other localizations, including brain tumors. The mean age of the consulted patients was 28.4 years (19 to 42 years). As part of the delayed motherhood program 60 ovarian stimulations followed by cryopreservation of oocytes and embryos were performed, 6 intraoperative collecting of the ovarian cortex for OTO-IVM were performed (in 3 cases oocytes cryopreservation was successful). More than 40 men were sent for semen cryopreservation, which is 71% of all consulted male patients.

Conclusion The introduction of fertility preservation technologies into the treatment of oncological pregnant women demonstrates a high demand both among oncological patients and clinicians. An important aspect is the understanding that the leading role in the fertility preservation of oncological patients belongs to the oncological concilium, which must be carried out in a multidisciplinary way in specialised centers only.

Introduction/Background Vulvar cancer is a malignant disease appeared mostly in postmenopausal women. When the lesion appears prior, during pregnancy or in postpartum, it is a rare condition. Cervical and vulvar neoplasia are now diagnosed more and more during pregnancy and it is wellknown the relation between this neoplasia and Human Papilloma Virus (HPV) infection. The pregnancy outcome in these cases is the aim of our study.

Methodology Vulvar cancer was diagnosed in 284 patients in the last ten years, in our hospital. All the women were tested for HPV. Three cases only were pregnancy-related. The object of our study was the pregnancy outcome. In one of the pregnant patients, CIN grade 3 was also diagnosed.

Results All the patients were HPV positive. In all these patients healthy babies were delivered, all of them by Cesarean section. Vulvar cancer and CIN grade 3 were both diagnosed in a 26 years old second trimester pregnant patient monitored in our department of obstetrics. Her medical history revealed that she had before two babies, the first delivered vaginally and the second by C section. She was diagnosed during her actual pregnancy and treated for vulvar cancer by surgery. Radiotherapy was performed after the delivery by C section of a healthy, at term baby. Cervical and vulvar cancer by surgery. Radiotherapy was performed after the delivery by C section of a healthy, at term baby. Conization of the cervix was performed a couple of months later, when grade 3 CIN was diagnosed. The presence of HPV16 confirmed the theory that this viral infection is strongly considered the main factor in the etiology of both neoplastic diseases, vulvar cancer and cervical intraepithelial neoplasia.

Conclusion Pregnancy associated vulvar neoplasia is very rare. The management and long-term outcome for the mother and the baby are difficult to assess, but it is possible to have a normal, successful, at term delivery following the treatment for vulvar neoplasia.

2022-RA-1407-ESGO VARIATION IN OUTCOME REPORTING IN STUDIES OF FERTILITY SPARING SURGERY FOR CERVICAL CANCER: A SYSTEMATIC REVIEW

Introduction/Background Cervical cancer affects 3,197 UK women and 570,000 women worldwide annually, with peak incidence seen between 30–34 years age. For many, fertility-sparing surgery is an appealing option where possible. However, absence of large-scale data, along-with a notable variation in reported outcomes in relevant studies may undermine future efforts for consistent evidence synthesis. We aimed to systematically review the reported outcomes measured in studies that include women who underwent fertility-sparing surgery for cervical cancer and identify whether variation exists.

Methodology We searched MEDLINE, EMBASE, and CENTRAL from inception to February 2019. We included randomised controlled trials, cohort and observational studies, and case studies of more than 10 participants from January 1990 to date. We extracted data on study characteristics and all reported treatment outcomes.

Results 104 studies with a sum of 9535 participants were identified. Most studies reported on oncological outcomes (97/104), followed by fertility and pregnancy (86/104), post-operative complications (74/104), intra-operative complications (72/104), and quality-of-life (5). There was huge variation and heterogeneity in reported outcomes, with only 12% being good quality and 87% being of poor quality.

Conclusion There is significant heterogeneity in the reported outcomes. An agreed Core Outcome Set (COS) is necessary.